|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: PQLC2 |
Gene summary for PQLC2 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | PQLC2 | Gene ID | 54896 |
| Gene name | solute carrier family 66 member 1 | |
| Gene Alias | LAAT-1 | |
| Cytomap | 1p36.13 | |
| Gene Type | protein-coding | GO ID | GO:0003333 | UniProtAcc | A0A024RA97 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 54896 | PQLC2 | P1T-E | Human | Esophagus | ESCC | 4.62e-03 | 1.54e-01 | 0.0875 |
| 54896 | PQLC2 | P2T-E | Human | Esophagus | ESCC | 1.69e-16 | 2.75e-01 | 0.1177 |
| 54896 | PQLC2 | P4T-E | Human | Esophagus | ESCC | 6.14e-11 | 2.24e-01 | 0.1323 |
| 54896 | PQLC2 | P5T-E | Human | Esophagus | ESCC | 3.97e-04 | 9.61e-02 | 0.1327 |
| 54896 | PQLC2 | P8T-E | Human | Esophagus | ESCC | 9.35e-10 | 1.71e-01 | 0.0889 |
| 54896 | PQLC2 | P9T-E | Human | Esophagus | ESCC | 2.41e-06 | 1.58e-01 | 0.1131 |
| 54896 | PQLC2 | P10T-E | Human | Esophagus | ESCC | 7.31e-14 | 2.80e-01 | 0.116 |
| 54896 | PQLC2 | P11T-E | Human | Esophagus | ESCC | 1.13e-06 | 2.55e-01 | 0.1426 |
| 54896 | PQLC2 | P12T-E | Human | Esophagus | ESCC | 7.31e-14 | 2.61e-01 | 0.1122 |
| 54896 | PQLC2 | P15T-E | Human | Esophagus | ESCC | 2.31e-15 | 2.79e-01 | 0.1149 |
| 54896 | PQLC2 | P16T-E | Human | Esophagus | ESCC | 8.84e-05 | 1.20e-01 | 0.1153 |
| 54896 | PQLC2 | P17T-E | Human | Esophagus | ESCC | 1.49e-05 | 2.27e-01 | 0.1278 |
| 54896 | PQLC2 | P19T-E | Human | Esophagus | ESCC | 2.24e-09 | 5.35e-01 | 0.1662 |
| 54896 | PQLC2 | P20T-E | Human | Esophagus | ESCC | 4.83e-12 | 2.69e-01 | 0.1124 |
| 54896 | PQLC2 | P21T-E | Human | Esophagus | ESCC | 2.25e-22 | 4.35e-01 | 0.1617 |
| 54896 | PQLC2 | P22T-E | Human | Esophagus | ESCC | 9.02e-11 | 2.07e-01 | 0.1236 |
| 54896 | PQLC2 | P23T-E | Human | Esophagus | ESCC | 6.47e-17 | 3.58e-01 | 0.108 |
| 54896 | PQLC2 | P24T-E | Human | Esophagus | ESCC | 4.12e-11 | 2.19e-01 | 0.1287 |
| 54896 | PQLC2 | P26T-E | Human | Esophagus | ESCC | 5.79e-16 | 2.17e-01 | 0.1276 |
| 54896 | PQLC2 | P27T-E | Human | Esophagus | ESCC | 7.30e-09 | 2.33e-01 | 0.1055 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| PQLC2 | SNV | Missense_Mutation | c.653C>A | p.Ser218Tyr | p.S218Y | Q6ZP29 | protein_coding | tolerated(0.47) | benign(0.062) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PQLC2 | SNV | Missense_Mutation | c.53N>A | p.Ser18Tyr | p.S18Y | Q6ZP29 | protein_coding | deleterious(0) | benign(0.396) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| PQLC2 | SNV | Missense_Mutation | c.292C>A | p.Gln98Lys | p.Q98K | Q6ZP29 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-IR-A3LK-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | PD | |
| PQLC2 | SNV | Missense_Mutation | novel | c.199N>C | p.Asp67His | p.D67H | Q6ZP29 | protein_coding | tolerated(0.14) | possibly_damaging(0.841) | TCGA-VS-A94X-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| PQLC2 | SNV | Missense_Mutation | c.59A>G | p.Gln20Arg | p.Q20R | Q6ZP29 | protein_coding | tolerated(1) | benign(0.001) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| PQLC2 | SNV | Missense_Mutation | rs756272440 | c.683C>T | p.Thr228Met | p.T228M | Q6ZP29 | protein_coding | tolerated(0.15) | benign(0.067) | TCGA-AA-3864-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| PQLC2 | SNV | Missense_Mutation | rs546350739 | c.106N>A | p.Glu36Lys | p.E36K | Q6ZP29 | protein_coding | tolerated(0.29) | benign(0.001) | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| PQLC2 | SNV | Missense_Mutation | rs755077935 | c.206C>T | p.Ala69Val | p.A69V | Q6ZP29 | protein_coding | deleterious(0) | possibly_damaging(0.883) | TCGA-CM-6162-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
| PQLC2 | insertion | Frame_Shift_Ins | novel | c.579_580dupGT | p.Leu194CysfsTer31 | p.L194Cfs*31 | Q6ZP29 | protein_coding | TCGA-F4-6569-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Ancillary | leucovorin | CR | ||
| PQLC2 | SNV | Missense_Mutation | c.661N>A | p.Ala221Thr | p.A221T | Q6ZP29 | protein_coding | deleterious(0.01) | benign(0.322) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |